Epstein-Barr/JJ
virus/NN
nuclear/JJ
antigen/NN
2/CD
transactivates/VBZ
latent/JJ
membrane/NN
protein/NN
LMP1/NN
./.

Several/JJ
lines/NNS
of/IN
evidence/NN
are/VBP
compatible/JJ
with/IN
the/DT
hypothesis/NN
that/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
nuclear/JJ
antigen/NN
2/CD
(/(
EBNA-2/NN
)/)
or/CC
leader/NN
protein/NN
(/(
EBNA-LP/NN
)/)
affects/VBZ
expression/NN
of/IN
the/DT
EBV/NN
latent/JJ
infection/NN
membrane/NN
protein/NN
LMP1/NN
./.
=====
We/PRP
now/RB
demonstrate/VBP
the/DT
following/NN
./.
=====
(/(
i/LS
)/)
Acute/JJ
transfection/NN
and/CC
expression/NN
of/IN
EBNA-2/NN
under/IN
control/NN
of/IN
simian/JJ
virus/NN
40/CD
or/CC
Moloney/NN
murine/JJ
leukemia/NN
virus/NN
promoters/NNS
resulted/VBD
in/IN
increased/VBN
LMP1/NN
expression/NN
in/IN
P3HR-1-infected/JJ
Burkitt/NN
's/POS
lymphoma/NN
cells/NNS
and/CC
the/DT
P3HR-1/NN
or/CC
Daudi/NN
cell/NN
line/NN
./.
=====
(/(
ii/LS
)/)
Transfection/NN
and/CC
expression/NN
of/IN
EBNA-LP/NN
alone/RB
had/VBD
no/DT
effect/NN
on/IN
LMP1/NN
expression/NN
and/CC
did/VBD
not/RB
act/VB
synergistically/RB
with/IN
EBNA-2/NN
to/TO
affect/VB
LMP1/NN
expression/NN
./.
=====
(/(
iii/LS
)/)
LMP1/NN
expression/NN
in/IN
Daudi/NN
and/CC
P3HR-1-infected/JJ
cells/NNS
was/VBD
controlled/VBN
at/IN
the/DT
mRNA/NN
level/NN
,/,
and/CC
EBNA-2/NN
expression/NN
in/IN
Daudi/NN
cells/NNS
increased/VBD
LMP1/NN
mRNA/NN
./.
=====
(/(
iv/LS
)/)
No/DT
other/JJ
EBV/NN
genes/NNS
were/VBD
required/VBN
for/IN
EBNA-2/NN
transactivation/NN
of/IN
LMP1/NN
since/IN
cotransfection/NN
of/IN
recombinant/JJ
EBNA-2/NN
expression/NN
vectors/NNS
and/CC
genomic/JJ
LMP1/NN
DNA/NN
fragments/NNS
enhanced/VBD
LMP1/NN
expression/NN
in/IN
the/DT
EBV-negative/JJ
B-lymphoma/NN
cell/NN
lines/NNS
BJAB/NN
,/,
Louckes/NN
,/,
and/CC
BL30/NN
./.
=====
(/(
v/LS
)/)
An/DT
EBNA-2-responsive/JJ
element/NN
was/VBD
found/VBN
within/IN
the/DT
-512/CD
to/TO
+40/CD
LMP1/NN
DNA/NN
since/IN
this/DT
DNA/NN
linked/VBN
to/TO
a/DT
chloramphenicol/NN
acetyltransferase/NN
reporter/NN
gene/NN
was/VBD
transactivated/VBN
by/IN
cotransfection/NN
with/IN
an/DT
EBNA-2/NN
expression/NN
vector/NN
./.
=====
(/(
vi/LS
)/)
The/DT
EBV/NN
type/NN
2/CD
EBNA-2/NN
transactivated/VBD
LMP1/NN
as/RB
well/RB
as/IN
the/DT
EBV/NN
type/NN
1/CD
EBNA-2/NN
./.
=====
(/(
vii/LS
)/)
Two/CD
deletions/NNS
within/IN
the/DT
EBNA-2/NN
gene/NN
which/WDT
rendered/VBD
EBV/NN
transformation/NN
incompetent/JJ
did/VBD
not/RB
transactivate/VB
LMP1/NN
,/,
whereas/IN
a/DT
transformation-competent/JJ
EBNA-2/NN
deletion/NN
mutant/NN
did/VBD
transactivate/VB
LMP1/NN
./.
=====
LMP1/NN
is/VBZ
a/DT
potent/JJ
effector/NN
of/IN
B-lymphocyte/NN
activation/NN
and/CC
can/MD
act/VB
synergistically/RB
with/IN
EBNA-2/NN
to/TO
induce/VB
cellular/JJ
CD23/NN
gene/NN
expression/NN
./.
=====
Thus/RB
,/,
EBNA-2/NN
transactivation/NN
of/IN
LMP1/NN
amplifies/VBZ
the/DT
biological/JJ
impact/NN
of/IN
EBNA-2/NN
and/CC
underscores/VBZ
its/PRP$
central/JJ
role/NN
in/IN
EBV-induced/JJ
growth/NN
transformation/NN
./.